Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | UBE2N | P61088 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | RRM1 | P23921 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023565 | 0.95 | TSHR (0.46) | TSHRMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL1026429 | 0.88 | TSHR (0.53) | TSHRMEN1MAPK1KMT2ATDP1 | |
| SCHEMBL1952531 | 0.85 | TSHR (0.55) | TSHRMEN1KMT2ATDP1MAPT | |
| SCHEMBL1023566 | 0.85 | MEN1 (0.39) | TSHRMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL1022837 | 0.84 | TSHR (0.49) | TSHRMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1022938 | 0.82 | TSHR (0.48) | TSHRMAPK1TDP1HTT | |
| SCHEMBL1021098 | 0.80 | TSHR (0.53) | TSHRKMT2AALDH1A1TDP1HTT | |
| SCHEMBL2923735 | 0.80 | TSHR (0.46) | TSHRMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1021773 | 0.78 | TSHR (0.55) | TSHRMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL1953136 | 0.77 | TSHR (0.54) | TSHRSMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145358-B2 | N-substituted carbamic acid ester production method, isocyanate production method using such N-substituted carbamic acid ester, and composition for transfer and storage of N-substituted carbamic acid ester comprising N-substituted carbamic acid ester and aromatic hydroxy compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-09-29 | — | — | US | disclosed |
| US-20140194644-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, and Composition for Transfer and Storage of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-07-10 | — | — | US | disclosed |
| US-8053595-B2 | Process for producing isocyanates | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20110133121-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2088137-B1 | A PROCESS FOR PRODUCING ISOCYANATES | ASAHI KASEI CHEMICALS CORP (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110133121-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, And Composition For Transfer And Storage Of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | CPS1, ALKBH3, RCC1 | TSHR 4686/4885MEN1 1225/4885MAPK1 4376/4885 |
| US-20140194644-A1 | N-Substituted Carbamic Acid Ester Production Method, Isocyanate Production Method Using Such N-Substituted Carbamic Acid Ester, and Composition for Transfer and Storage of N-Substituted Carbamic Acid Ester Comprising N-Substituted Carbamic Acid Ester and Aromatic Hydroxy Compound | CPS1, ALKBH3, RCC1 | TSHR 4686/4885MEN1 1225/4885MAPK1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.